Vexim: +17% growth in sales in 2017 up to €21.6 million

  • Strong International growth: +42% up to €2.4 million
  • Continued growth in Europe: +14% up to €19.2 million
  • More than 60,500 SpineJack® implants sold since 2011

 

VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated sales results for the full year 2017, as of December 31st, 2017.

Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies
Other news
Median Technologies records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
Hungary and the Netherlands approve Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company’s strategy for innovation and partnerships